First United Bank & Trust Has $3.01 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

First United Bank & Trust lowered its stake in Johnson & Johnson (NYSE:JNJ) by 1.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,657 shares of the company’s stock after selling 206 shares during the period. Johnson & Johnson accounts for 1.2% of First United Bank & Trust’s holdings, making the stock its 24th largest holding. First United Bank & Trust’s holdings in Johnson & Johnson were worth $3,013,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently modified their holdings of JNJ. Newton One Investments LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth $31,000. RPg Family Wealth Advisory LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth $32,000. Robbins Farley LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth $33,000. Lion Street Advisors LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth $36,000. Finally, Alpha Paradigm Partners LLC bought a new position in Johnson & Johnson during the second quarter worth $47,000. Hedge funds and other institutional investors own 67.14% of the company’s stock.

JNJ opened at $160.24 on Thursday. Johnson & Johnson has a 1-year low of $142.86 and a 1-year high of $179.92. The company has a current ratio of 1.34, a quick ratio of 1.11 and a debt-to-equity ratio of 0.43. The company has a market cap of $421.85 billion, a P/E ratio of 23.95, a price-to-earnings-growth ratio of 2.38 and a beta of 0.71. The company has a fifty day moving average price of $162.64 and a two-hundred day moving average price of $167.35.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Monday, October 18th. The company reported $2.60 earnings per share for the quarter, beating the consensus estimate of $2.35 by $0.25. The firm had revenue of $23.34 billion during the quarter, compared to the consensus estimate of $23.72 billion. Johnson & Johnson had a net margin of 19.55% and a return on equity of 37.90%. The business’s revenue was up 10.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.20 earnings per share. On average, research analysts forecast that Johnson & Johnson will post 9.78 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 7th. Stockholders of record on Tuesday, November 23rd will be given a dividend of $1.06 per share. This represents a $4.24 annualized dividend and a dividend yield of 2.65%. The ex-dividend date is Monday, November 22nd. Johnson & Johnson’s payout ratio is presently 63.38%.

A number of brokerages recently weighed in on JNJ. Morgan Stanley downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 target price for the company. in a research note on Tuesday, September 7th. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $172.00 target price for the company in a research note on Friday, October 22nd. SVB Leerink reissued a “buy” rating on shares of Johnson & Johnson in a research note on Thursday, July 29th. Raymond James lowered their target price on shares of Johnson & Johnson from $183.00 to $178.00 and set an “outperform” rating for the company in a research note on Wednesday, October 20th. Finally, Wells Fargo & Company reissued a “buy” rating on shares of Johnson & Johnson in a research note on Thursday, October 7th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $187.78.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Article: Dividend Yield

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.